

NCI SBIR AND YOUR STATE:

VIRGINIA



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$14.7 million** in funding across **14 Phase II SBIR/STTR grants** to small businesses in Virginia. The following economic impact estimates quantify the program's contributions to the state's economy:



\$91.9M

IN TOTAL DIRECT SALES



\$349.1M

IN TOTAL ECONOMIC IMPACT



1.5K

JOBS CREATED



\$11.8M

IN STATE & LOCAL TAXES COLLECTED



11

COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Virginia: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$45.9M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

CARINA MEDICAL, LLC

Carina Medical, LLC leveraged SBIR funding to develop INT Contour™, an AI-based software for medical image analysis and segmentation of organs and lymph node groups. INT Contour™ received FDA approval in April 2022.

HEMOSONICS

UVA startup Hemosonics used SBIR funding to develop its Quantra™ Hemostasis System. Receiving 3 FDA approvals for evaluation of blood coagulation, Hemosonics won Medical Device Network Excellence Awards for Innovation in 2024 and Marketing in 2025.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.